Alexza Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 61

Alexza Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Alexza Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Alexza Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alexza Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alexza Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alexza Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Alexza Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alexza Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alexza Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alexza Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alexza Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Alexza Pharmaceuticals, Inc. Snapshot
Alexza Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Alexza Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Alexza Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Alexza Pharmaceuticals, Inc. – Pipeline Products Glance
Alexza Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Alexza Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Alexza Pharmaceuticals, Inc. – Drug Profiles
AZ-004
Product Description
Mechanism of Action
R&D Progress
AZ-001
Product Description
Mechanism of Action
R&D Progress
AZ-002
Product Description
Mechanism of Action
R&D Progress
AZ-104
Product Description
Mechanism of Action
R&D Progress
AZ-003
Product Description
Mechanism of Action
R&D Progress
AZ-007
Product Description
Mechanism of Action
R&D Progress
AZ-104
Product Description
Mechanism of Action
R&D Progress
Alexza Pharmaceuticals, Inc. – Pipeline Analysis
Alexza Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Alexza Pharmaceuticals, Inc. Pipeline Products By Target
Alexza Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Alexza Pharmaceuticals, Inc. – Recent Pipeline Updates
Alexza Pharmaceuticals, Inc. – Company Statement
Alexza Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 11, 2010: Alexza Receives Complete Response Letter For AZ-004 NDA
Oct 11, 2010: Alexza Receives Complete Response Letter For AZ-004 NDA
Jul 12, 2010: Alexza Updates Staccato Pipeline And Outlines Pipeline Development Strategy
May 26, 2010: Alexza Presents Additional Phase III Analyses and Phase I Cardiovascular Safety Data Of Staccato Loxapine
Feb 11, 2010: Alexza Announces AZ-004 PDUFA Goal Date Of October 11, 2010
Feb 11, 2010: Alexza Announces AZ-004 PDUFA Goal Date Of October 11, 2010
Feb 10, 2010: Alexza And Biovail Collaborate To Develop And Commercialize AZ-004 (Staccato Loxapine) In North America
Sep 14, 2009: Alexza Announces Preliminary Results Of Phase 2b Trial For AZ-104 In Patients With Migraine Headache
Jan 20, 2009: Alexza Initiates Phase 2b Trial Of AZ-104 In Patients With Migraine Headaches
Dec 09, 2008: Alexza Announces Positive Results Of Its Phase 3 Clinical Trial Of AZ-004
Financial Deals Landscape
Alexza Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Alexza Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Alexza Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Alexza Pharmaceuticals, Inc. Detailed Deal Summary
Acquisition
Alexza Pharmaceuticals Acquires Symphony Allegro From Symphony Capital
Venture Financing
Alexza Molecular Delivery Secures $52 Million In Second Round Of Financing
Alexza Molecular Delivery Secures $45 Million In First Round Of Financing
Equity Offering
Alexza Pharmaceuticals Completes Private Placement Of $19.7 Million
Alexza Pharmaceuticals Completes Private Placement Of $10 Million
Alexza Pharmaceuticals Completes Public Offering Of $70.73 Million
Alexza Pharmaceuticals Completes Initial Public Offering Of $50.6 Million
Alexza Pharmaceuticals Terminates Private Placement Of $50 Million With Azimuth
Alexza Pharmaceuticals Enters Into Licensing Agreement With Endo Pharmaceuticals
Endo Pharmaceuticals Terminates Agreement With Alexza Pharmaceuticals
Licensing Agreements
Alexza Pharmaceuticals Enters Into Licensing Agreement With Symphony Allegro
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Commercial And Military Flight Simulation - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Private Tutoring - Global Strategic Business Report